Public Health & Health Science Division, ULAB

Cannabis, derived from the Cannabis sativa plant, has historically been utilized for its medicinal properties, notably for pain management and symptom relief in various health conditions. Recent research has expanded its potential therapeutic applications, particularly in cancer treatment and chronic pain management. This paper explores the role of two primary cannabinoids, Delta9-tetrahydrocannabinol (THC) and cannabidiol (CBD), in addressing cancer-related symptoms and chronic pain. THC and CBD have demonstrated significant anti-tumor and anti-inflammatory activities, which are mediated through interactions with the endocannabinoid system (ECS). THC primarily targets CB1 receptors to modulate pain and neuroinflammation, while CBD exerts effects through a more complex mechanism involving various receptors, including CB2, TRPV1, and 5-HT1A. The paper reviews clinical and preclinical studies to elucidate the efficacy of these cannabinoids in alleviating symptoms such as pain, anxiety, and nausea in cancer patients and their role in enhancing traditional cancer treatments. Additionally, it addresses the potential risks and side effects associated with cannabinoid use, including cognitive and psychological effects linked to THC. The paper emphasizes the need for standardized dosing and formulation in cannabinoid therapies and calls for further research to optimize treatment protocols, assess long-term safety, and explore new therapeutic targets. The findings underscore the promising role of cannabinoids in improving the quality of life for cancer patients and managing chronic pain, highlighting their potential as adjunctive therapies in modern medicine.